Clinical Process Improvement With A Bedside Computerized Insulin Therapy Protocol For Blood Glucose Control (eProtocol-insulin) in Adult And Pediatric ICU Patients:Further Refinement and Validation of eProtocol-insulin

Intermountain Health Care, Inc.11 sites in 1 country200 target enrollmentFebruary 2006

ConditionsCritically Ill Hyperglycemia

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Critically Ill
Sponsor: Intermountain Health Care, Inc.
Enrollment: 200
Locations: 11
Primary Endpoint: The primary outcome variable during Phase I will be the acceptability of the eProtocol-insulin instructions (compliance of bedside clinicians with instructions: more than 90 % of all instructions accepted by the bedside clinician).
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The Purpose of this study is to:

Refine and validate a computerized bedside decision support tool blood glucose management in critically ill adult and pediatric ICU patients.
Monitor how often low blood sugar levels occur during use of the bedside tool.
Determine how the computerized tool effects the workload of the ICU nurses.

Detailed Description

This first phase will be a prospective cohort study. We will validate the bedside tool in at least 4 adult and at least 4 pediatric ICUs and if necessary we will modify the bedside tool. The computerized bedside tool will be considered refined if \>90% of the generated instructions are accepted and if the percent of glucose values in the 70-110 mg/dl range are equivalent to our pilot experience rate of 55%, and if the rate of glucose values less than or equal to 40 mg/dl is less than 0.5% of glucose measurements.

Registry

clinicaltrials.gov

Start Date

February 2006

End Date

December 2018

Last Updated

11 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Intermountain Health Care, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Pediatric ICU: Proposed indications by pediatric clinicians at participating ICUs for glucose control in their ICUs would include patients who require mechanical ventilation for greater than 24 hours and/or require a vasoactive infusion (e.g. dopamine \>3 mg/kg/min, dobutamine, epinephrine, or vasopressin).
•Adult ICUs: Proposed indications by clinicians in participating ICUs for glucose control in participating adult ICUs include critically ill patients with an anticipated ICU length of stay of 3 or more days.

Exclusion Criteria

•Pregnancy (negative pregnancy test required for females of child-bearing age)
•Age less than one month
•Inborn errors of metabolism that the clinician suspects will affect glucose homeostasis
•Acute or chronic liver disease with any documented episode of blood or plasma glucose \<60 mg/dl within the 24 hours prior to study entry
•Diabetic Ketoacidosis (critically ill patients with insulin dependent diabetes not in ketoacidosis will be eligible if attending physicians intend to use intravenous insulin as part of ordinary care)
•Severe chronic liver disease (Child-Pugh score \>10)

Outcomes

Primary Outcomes

The primary outcome variable during Phase I will be the acceptability of the eProtocol-insulin instructions (compliance of bedside clinicians with instructions: more than 90 % of all instructions accepted by the bedside clinician).

Time Frame: 3 years

Secondary Outcomes

Proportion of glucose determinations within the range of 70-110 mg/dl (3.9-6.1 mMol/l)(3 years)
Nursing perception of workload in comparison to ordinary care(3 years)